Progress in the application of mesenchymal stem cells to attenuate apoptosis in diabetic kidney disease

Area of Science:

• Nephrology
• Regenerative Medicine
• Cell Biology

Background:

• Diabetic kidney disease (DKD) presents a significant health challenge with high mortality and limited treatment options.
• Apoptosis, or programmed cell death, is a key driver in the progression of DKD.
• Mesenchymal stem cells (MSCs) offer potential therapeutic benefits for DKD through tissue regeneration and protective effects.

Purpose of the Study:

• To review the mechanisms of apoptosis in diabetic kidney disease.
• To examine the current research on the therapeutic roles of MSCs and MSC-derived extracellular vesicles (MSC-EVs) in DKD.
• To highlight the need for further investigation into MSC and MSC-EV regulatory pathways in DKD.

Main Methods:

• Comprehensive literature review of studies on apoptosis in DKD.
• Analysis of research on MSC transplantation and paracrine effects in DKD models.
• Evaluation of studies investigating MSC-EVs, including miRNA transfer, in DKD treatment.

Main Results:

• MSCs demonstrate protective effects in DKD by improving renal function, reducing blood glucose, and lowering urinary protein levels.
• MSCs and MSC-EVs can mitigate apoptosis in DKD through direct differentiation or paracrine signaling, including miRNA modulation.
• Existing research indicates MSCs and MSC-EVs are promising for DKD therapy, but mechanisms require deeper exploration.

Conclusions:

• Apoptosis is a critical factor in DKD pathogenesis, and MSC-based therapies show significant potential for mitigating this process.
• MSC-EVs offer a cell-free therapeutic strategy for DKD by delivering bioactive molecules that reduce apoptosis.
• Further research is essential to elucidate the intricate mechanisms of MSCs and MSC-EVs in combating DKD and to optimize their clinical application.